Capital Blue Cross is partnering with the Mark Cuban Cost Plus Drug Co. to make lower‑cost biosimilar alternatives to Humira and Stelara available to commercial members.

The company expects to file for regulatory approval of a label expansion for Ozempic pills in the United States and Rybelsus in the European Union in the second half of this year.

More than 7 in 10 physicians now report using AI in clinical practice, up from 48% last year.

HHS Secretary Robert F. Kennedy Jr. defended his agency's policies on Medicaid funding, maternal health and other issues during a contentious congressional hearing on Tuesday.

A federal judge in Oregon on Monday issued an order barring the U.S. Department of Health and Human Services from implementing gender-treatment restrictions in 21 states and the District of Columbia.

Seven in 10 retirees and 4 in 5 workers are concerned that the government will make changes to the retirement system.

"Employers can offer markedly different health benefit experiences for workers, affecting access to care, the affordability of coverage and the scope of benefits provided," a new report from Peterson-KFF Health System Tracker said.

"People's access to employer-sponsored insurance depends on the availability and cost of coverage where they or a family member work," according to a new report from the Peterson-KFF Health System Tracker.